Copyright
©2014 Baishideng Publishing Group Co.
World J Diabetes. Apr 15, 2014; 5(2): 128-140
Published online Apr 15, 2014. doi: 10.4239/wjd.v5.i2.128
Published online Apr 15, 2014. doi: 10.4239/wjd.v5.i2.128
Table 1 Type 2 diabetes mellitus susceptibility genes
| Gene | Chr | Odds ratio | RAF | Study | Function and probable mechanism | Ref |
| ADAMTS9 | 3 | 1.09-1.05 | 0.68-0.81 | MA | Metalloproteinase/Insulin action | [22–24] |
| ADCY5 | 3 | 1.12 | 0.78 | MA | Adenylyl cyclases/Insulin action | [25] |
| ANK1 | 8 | 1.09 | 0.76 | MA, CC | Cell stability/β-cell function | [26–28] |
| ANKRD55 | 5 | 1.08 | 0.7 | MA, CC | Insulin action | [26,27] |
| ANKS1A | 6 | 1.11 | 0.91 | GWAS | Pathway regulator/Unknown | [29] |
| ARAP1 | 11 | 1.08-1.14 | 0.81-0.88 | GWAS, MA | Actin cytoskeleton modulator/β-cell function | [22,24] |
| BCAR1 | 16 | 1.12 | 0.89 | MA, CC | Docking protein/β-cell function | [26,27] |
| BCL2 | 18 | 1.09 | 0.64 | GWAS | Cell death regulator/Unknown | [24] |
| BCL11A | 2 | 1.08-1.09 | 0.46 | MA | Zinc finger/β-cell function | [22] |
| CAMK1DCDC123 | 10 | 1.07-1.11 | 0.18 | LA, MA | Protein kinase/β-cell function | [22–24] |
| Mitotic protein/β-cell function | ||||||
| CAPN10 | 2 | 1.09-1.18 | 0.73-0.96 | MA | Calpain cysteine protease/Insulin action | [30–33] |
| CDKAL1 | 6 | 1.10-1.20 | 0.27-0.31 | GWAS, MA | β-cell function | [24,34–36] |
| CDKN2ACDKN2B | 9 | 1.19-1.20 | 0.82-0.83 | GWAS | Cyclin-dependent kinase inhibitor/β-cell function | [24,34,35] |
| CENTD2 | 11 | 1.08-1.13 | 0.81-0.88 | GWAS | β-cell function | [22,24] |
| CHCHD9TLE4 | 9 | 1.11-1.20 | 0.93 | MA | Unknown | [22] |
| CILP2 | 19 | 1.13 | 0.08 | MA, CC | Unknown | [26,27] |
| DGKB | 7 | 1.04-1.06 | 0.47-0.54 | MA | Diacylglycerol kinase/Insulin action | [24,25] |
| DUSP9 | X | 1.09-1.27 | 0.12-0.77 | MA | Phosphatase | [22,24] |
| FOLH1 | 11 | 1.10 | 0.09 | GWAS | Transmembrane glycoprotein/Unknown | [24] |
| FTO | 16 | 1.06-1.27 | 0.38-0.41 | GWAS, MA | Metabolic regulator/Insulin action | [24,37] |
| GATAD2A | 19 | 1.12 | 0.08 | GWAS | Transcriptional repressor/Unknown | [24] |
| GCK | 7 | 1.07 | 0.20 | MA | Glucokinase/Insulin action | [25] |
| GCKR | 2 | 1.06-1.09 | 0.59-0.62 | MA | Glucokinase regulator/Insulin action | [24,25] |
| GIPR | 19 | 1.10 | 0.27 | GWAS | G-protein coupled receptor/Unknown | [24] |
| GRB14 | 2 | 1.07 | 0.60 | MA, GCS | Adapter protein/Insulin action | [26,27] |
| HFE | 6 | 1.12 | 0.29 | MA | Membrane protein/Unknown | [38] |
| HHEX | 10 | 1.12-1.13 | 0.53-0.60 | AL, MA | Transcriptional repressor/ | [22,24,34,39] |
| IDE | Intracellular insulin degradation/ | |||||
| KIF11 | Motor protein | |||||
| HMG20A | 15 | 1.08 | 0.68 | MA, GCS | Chromatin-associated protein/Unknown | [26,27] |
| HMGA1 | 6 | 1.34-15.8 | 0.10 | GCS | Transcriptional regulator/Insulin action | [40-42] |
| HMGA2 | 12 | 1.10-1.20 | 0.09-0.10 | MA | Transcriptional regulator | [22,24] |
| HNF1A | 12 | 1.07-1.14 | 0.77-0.85 | MA | Pancreatic and liver transcriptional activator | [22,24] |
| HNF1B | 17 | 1.08-1.17 | 0.47-0.51 | GCS, MA | Transcription factor/β-cell function | [22,24] |
| IGF2BP2 | 3 | 1.14 | 0.29-0.32 | GWAS, MA | Binding protein/β-cell function | [22,24,34,35] |
| IRS1 | 2 | 1.09-1.12 | 0.64-0.67 | GCS, MA | Insulin signaling element/Insulin action | [22,24,43] |
| JAZF1 | 7 | 1.10 | 0.52 | MA | Zinc finger/β-cell function | [22,23] |
| KCNJ11 | 11 | 1.09-1.14 | 0.37-0.47 | GCS, MA | Potassium channel/β-cell function | [22,24,34,44] |
| KCNQ1 | 11 | 1.08-1.23 | 0.44 | GWAS | Potassium channel/β-cell function | [22,45,46] |
| KLF14 | 7 | 1.07-1.10 | 0.55 | MA | Transcription factor/Insulin action | [22] |
| KLHDC5 | 12 | 1.10 | 0.80 | MA, CC | Mitotic progression and cytokinesis/Unknown | [26,27] |
| LAMA1 | 18 | 1.13 | 0.38 | GWAS | Cellular migration mediator/Unknown | [29] |
| MC4R | 18 | 1.08 | 0.27 | MA, CC | G-protein–coupled receptor/Unknown | [26,27] |
| MTNR1B | 11 | 1.05-1.08 | 0.28-0.30 | GWAS, MA | Melatonin receptor/β-cell function | [24,47-49] |
| NOTCH2 | 1 | 1.06-1.13 | 0.10-0.11 | MA | Membrane receptor | [22-24] |
| PPARG | 3 | 1.11-1.17 | 0.85-0.88 | GCS, MA | Nuclear receptor/Insulin action | [22,24,34,50] |
| PRC1 | 15 | 1.07-1.10 | 0.22 | MA | Cytokinesis regulator | [22] |
| PROX1 | 1 | 1.07 | 0.50 | MA | Homeobox transcription factor/Insulin action | [25] |
| PTPRD | 9 | 1.57 | 0.10 | GWAS | Protein tyrosine phosphatase | [51] |
| RBMS1 | 2 | 1.11-1.08 | 0.79-0.83 | MA | DNA modulator/Insulin action | [24,52] |
| SLC2A2 | 3 | 1.06 | 0.74 | GWAS | Glucose sensor/β-cell function | [24] |
| SLC30A8 | 8 | 1.11-1.18 | 0.65-0.70 | GWAS, MA | Zinc efflux transporter/β-cell function | [22,24,25,34,53] |
| SREBF1 | 17 | 1.07 | 0.38 | GWAS | Lipid transcriptional regulator/Unknown | [24] |
| SRR | 17 | 1.28 | 0.69 | GWAS | Serine racemase | [51] |
| TCF7L2 | 10 | 1.31-1.71 | 0.26-0.30 | LA, MA,GWAS | Participates in the Wnt signaling pathway/β-cell function | [21,22,24,34] |
| THADA | 2 | 1.15 | 0.90 | MA | Thyroid adenoma-associated protein/β-cell function | [22-24] |
| TH/INS | 11 | 1.14 | 0.39 | GWAS | Catecholamine synthesis/Unknown | [24] |
| TLE1 | 9 | 1.07 | 0.57 | MA, CC | Transcriptional corepressor/Unknown | [26,27] |
| TP53INP1 | 8 | 1.06-1.11 | 0.48 | MA | Proapoptotic protein/Unknown | [22] |
| TSPAN8 | 12 | 1.06-1.09 | 0.27-0.71 | MA | Cell surface glycoprotein/β-cell function | [22-24] |
| LGR5 | G-protein coupled receptor/β-cell function | |||||
| WFS1 | 4 | 1.10-1.13 | 0.60-0.73 | GCS | Transmembrane protein/β-cell function | [22,24,54,55] |
| ZBED3 | 5 | 1.08-1.16 | 0.26 | MA | Zinc finger/b-cell function | [22] |
| ZFAND6 | 15 | 1.01-1.11 | 0.60-0.72 | MA | Zinc finger/β-cell function | [22,24] |
| ZMIZ1 | 10 | 1.08 | 0.52 | MA, CC | Transcriptional regulator/Unknown | [26,27] |
| Haplogroup B | mtDNA | 1.52 | 0.25 | GCS | [56] | |
| OriB | mtDNA | 1.10 | 0.30 | MA | [57] |
- Citation: Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of type 2 diabetes mellitus. World J Diabetes 2014; 5(2): 128-140
- URL: https://www.wjgnet.com/1948-9358/full/v5/i2/128.htm
- DOI: https://dx.doi.org/10.4239/wjd.v5.i2.128
